Navigation Links
CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis
Date:10/15/2009

reatic enzyme replacement therapies in order to remain on the market. By April 2010, all pancreatic enzyme replacement therapies are required to have approved NDAs and must be manufactured under the new guidelines.

Important Safety Information

Warnings and precautions include fibrosing colonopathy, a rare, serious adverse reaction that has been described in association with high-dose use of pancreatic enzyme replacement therapy in the treatment of cystic fibrosis patients. Caution should be exercised when doses of CREON® exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day). Care should be taken to ensure that CREON® is not chewed or retained in the mouth to avoid irritation of oral mucosa. Caution should be exercised when prescribing CREON® to patients with gout, renal impairment, or hyperuricemia. There is theoretical risk of viral transmission with all pancreatic enzyme products, including CREON®. Caution should be exercised when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.

In the clinical study used to demonstrate the efficacy and safety of FDA-approved CREON®, the incidence of adverse events (regardless of causality) was higher during placebo treatment (71%) than during CREON® treatment (50%). Treatment-emergent adverse events occurring in at least two patients (greater than or equal to 6%) receiving CREON® or placebo were abdominal pain, abdominal pain upper, abnormal feces, cough, dizziness, flatulence, headache, and weight decreased.

CREON® has been approved with a Risk Evaluation and Mitigation Strategy (REMS) to ensure that the benefits of the drug outweigh its risks. As part of the REMS, a Medication Guide with important dosing and safety information applicable to this class of products, including CREON®, is provided for patients and caregivers, w
'/>"/>

SOURCE Solvay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Results Published In Journal of Cystic Fibrosis Confirm CREON(R) (pancrelipase) Delayed-Release Capsules Improves Fat Absorption in Patients With Cystic Fibrosis
2. Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets
3. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
4. GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer
5. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
6. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
7. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
8. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
9. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
10. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
11. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Shakti, LLC, today announced that it has changed its name ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... our transformation into a company focused on patent claim analysis ... validity." In ... the Company commenced a corporate re-branding initiative in order to ...
(Date:8/28/2015)... Perrigo Company plc ("Perrigo") (NYSE: PRGO ; TASE) ... MYL ) shareholder vote regarding its planned unsolicited offer ... offer to Perrigo shareholders have always been, and will ... of the value available to Perrigo shareholders, and do ... allowed its shareholders to consider," said Joseph C. ...
(Date:8/28/2015)... , Aug. 28, 2015  Perrigo Company plc ... it has completed the acquisition of leading OTC brands ... €200 million. The transaction is a clear demonstration of ... Company,s leading European distribution network spanning 36 countries.  ... C. Papa commented, "We are excited to complete ...
Breaking Medicine Technology:IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... pharmacy was launched after the company had studied the market ... reliable and trustworthy places to shop for high quality prescription ... launching a website that would offer a full range of ... patience. The new drugstore is bound to become a popular ...
... 16 Novartis announced today that new six-year data ... Reclast® (zoledronic acid) injection in postmenopausal women with osteoporosis.(1) ... this weekend at the annual meeting of the American ... ON, Canada. The study showed that Reclast ...
Cached Medicine Technology:New Online Pharmacy RxBuys.com is Launched by One of the Leading Pharmaceutical Companies, Rx Corp 2Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 2Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 3Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 4Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 5Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 6
(Date:8/28/2015)... ... ... Dr. Gregory K. Toumayan, D.C., Q.M.E., is now treating patients with back ... hip pain, neck pain, stiffness, muscle spasms, and numbness. , Dr. Toumayan received ... went on to earn his title of Doctor of Chiropractic from the Palmer College ...
(Date:8/28/2015)... ... August 28, 2015 , ... SmartPractice Calendars ... Personalized with practice contact information and logos, Calendars stand alone as functional brand-building ... Calendars into seasonal mailings, thank you and welcome communications, and to complement statements ...
(Date:8/28/2015)... ... ... The Quatela Center for Plastic Surgery is excited to bring patients the ... by the Food and Drug Administration to eliminate submental fat, also known as the ... are among the premier cosmetic surgeons in Rochester to offer this innovative procedure.     , ...
(Date:8/28/2015)... ... August 28, 2015 , ... Northridge dentists Dr. Elyson and Dr. ... $199, patients can currently receive a one hour treatment of this teeth whitening option. ... includes a number of unique features that can turn teeth up to nine shades ...
(Date:8/28/2015)... ... August 28, 2015 , ... Mendon, IL, home of ... music and good people, all for a good cause. In its second year, the ... once more by Best Drug Rehabilitation. The “Mission” of “Music With A Mission” is ...
Breaking Medicine News(10 mins):Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2
... The United States Agency,for International Development (USAID) is ... of Georgia in response to the crisis situation,bringing the ... The Georgian government has identified sanitation and hygiene,facilities, ... and,canned foods as priority needs at this time. To ...
... 15 As part of its mission to,drive ... The,Michael J. Fox Foundation today announced that it ... to $1 million if all,milestones are met to ... technology for the treatment of Parkinson,s disease., ...
... Together to Promote Health Care Reform as the Top ... the Next President and Congress, WASHINGTON, Aug. 15 ... health care reform in 1993-1994, will be back on,television to ... the,agenda., Airing throughout the Democratic and Republican conventions, the ...
... while others spend , , FRIDAY, Aug. 15 (HealthDay News) -- ... the economy or old habits. , Psychologists and marketing experts ... plus your sense of well-being and your spending style, could ... , "Some people think, ,We have no incentive, that,s why ...
... drugs reduce closing of heart arteries, study shows , , ... perils facing obese people after they have the bypass ... a study finds. , The study was done to ... of obesity in such cases, said Dr. Christina C. ...
... than girls to have childhood asthma, but, when compared to ... it in adolescence and have a decreased incidence of asthma ... a buried mechanism in asthma development, according to a prospective ... children with mild to moderate asthma over a period of ...
Cached Medicine News:Health News:USAID Sends Humanitarian Assistance to the People of Georgia 2Health News:Michael J. Fox Foundation Awards One Million Dollars for Development of 'Trojan Horse' Delivery Technology to Treat Parkinson's Disease 2Health News:Michael J. Fox Foundation Awards One Million Dollars for Development of 'Trojan Horse' Delivery Technology to Treat Parkinson's Disease 3Health News:'Harry and Louise' Icons Return To Promote Health Care Reform In New Ad 2Health News:Money Matters 2Health News:Money Matters 3Health News:Statins Help Obese People After Bypass Surgery 2Health News:Statins Help Obese People After Bypass Surgery 3Health News:Asthma in boys may be just a phase, but for girls it may be there to stay 2
For accurately monitoring heart and breath sounds....
For accurately monitoring core temperature and heart and breath sounds....
For accurately monitoring core temperature and heart and breath sounds....
... Level 1 enables ... multiparameter patient monitors to ... series. Our temperature monitoring ... cables are superior in ...
Medicine Products: